0000899243-22-037482.txt : 20221202 0000899243-22-037482.hdr.sgml : 20221202 20221202175229 ACCESSION NUMBER: 0000899243-22-037482 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221201 FILED AS OF DATE: 20221202 DATE AS OF CHANGE: 20221202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cheng Andrew CENTRAL INDEX KEY: 0001778307 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38944 FILM NUMBER: 221443205 MAIL ADDRESS: STREET 1: 170 HARBOR WAY, 3RD FLOOR STREET 2: C/O AKERO THERAPEUTICS, INC. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akero Therapeutics, Inc. CENTRAL INDEX KEY: 0001744659 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-487-6488 MAIL ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-12-01 0 0001744659 Akero Therapeutics, Inc. AKRO 0001778307 Cheng Andrew C/O AKERO THERAPEUTICS, INC. 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 1 1 0 0 President & CEO Common Stock 2022-12-01 4 M 0 10000 0.615 A 320148 D Common Stock 2022-12-01 4 S 0 10000 46.07 D 310148 D Stock Option (Right to Buy) 0.615 2022-12-01 4 M 0 10000 0.00 D 2028-10-17 Common Stock 10000 210868 D The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.79 to $46.62, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. The options are vested and currently exercisable. /s/ Jonathan Young, Attorney-in-Fact 2022-12-02